Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation to: ...
ENHERTU Plus Pertuzumab Approved in the U.S. for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer ...
Valvular heart disease decreases the survival rate in cancer patients. Valve replacement surgeries provide a key benefit up to 72% all-cause-mortality reduction.
Neural and computational evidence reveals that real-world size is a temporally late, semantically grounded, and hierarchically stable dimension of object representation in both human brains and ...
Investing.com -- DBV Technologies stock surged 30% after the company announced positive results from its Phase III VITESSE clinical trial for VIASKIN Peanut, a treatment for peanut allergies in ...
Investing.com -- DBV Technologies (NASDAQ:DBVT) stock soared 65.2% in after-hours trading Tuesday following the announcement of positive topline results from its Phase 3 VITESSE trial for the VIASKIN ...
This study provides useful insights into addressing the question of whether the prevalence of autoimmune disease could be driven by sex differences in the T cell receptor (TCR) repertoire, correlating ...
BlackRock Frontiers Investment Trust Plc - Final Results ...
Editor's Note: APYs listed in this article are up-to-date as of the time of publication. They may fluctuate (up or down) as the Fed rate changes. CNBC Select will update as changes are made public.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback